Fig. 4.
![Fig. 4. Hematologic relapse. / Hematologic relapse of CML after BMT using MSD, matched, or partially matched URD in CP1 ([A] n = 369, 1244, 401, respectively;P = .24) and beyond CP (accelerated phase/blast phase; [B] n = 80, 536, 262, respectively; P = .54).](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/99/6/10.1182_blood.v99.6.1971/6/h80622296004.jpeg?Expires=1725264085&Signature=QAwF8QeAV6WdOnOYXAbSzMTBh3CupZU6XBONoQgWIpTD-ApqDpZV4n~ELBMpuF0eKWx4Xvp0G4YPDHdKuKR7mrV8byEwutJBnSQn4~M-oBv2ifRY8KpX1q2AWFmQXqqMtHc1BjO9Xw6qrWM1fmhhQH9SD5KsFPsVp05ZlBzX79fOfhaqgwEUHuhsxabWfOo8cusS~4G0vxntpcTlx1jPT4R4vh1TaXKqC1s7MdFs3InKv4fQEEzZhjOed5QUm~55TA-7DA1CqhIewaRBSTjCKhbPnFCCSo2EL8SFvYQmzikaYFdaLuImYMo2yEs7tPFSLOhFCbvkXkAERpiON6C6Nw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Hematologic relapse.
Hematologic relapse of CML after BMT using MSD, matched, or partially matched URD in CP1 ([A] n = 369, 1244, 401, respectively;P = .24) and beyond CP (accelerated phase/blast phase; [B] n = 80, 536, 262, respectively; P = .54).
